$NORD News

Nordicus Partners Corporation Corporate Update

NoviThera has initiated the first efficacy animal studies

Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in the treatment of experimental periodontitis in Wistar rats.

Orocidin develops novel cGMP manufacturing process in collaboration with Syngene

Nordicus Partners Corporation Announces The Formation Of A New Company, NoviThera ApS

Nordicus Partners Corporation Applies to Uplist to the Nasdaq Capital Market

Nordicus Partners Files To Uplist Common Stock To Nasdaq Capital Market

Nordicus Partners Corporation Appoints Three New Members to Its Board of Directors

Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia

Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in Dogs

Orocidin and Syngene Partner to Accelerate Biotech Innovation

Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study

Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia

Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment

Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin’s Breakthrough Treatment for Periodontitis

Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025

NORDICUS now trading under symbol NORD

Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S

Nordicus Partners Corporation Acquires Bio-Convert ApS

Nordicus Partners Corporation Announces Reverse Stock Split